title: Calcium Channel Blockers--Benefits Upon Vascular Biology in Hypertensive Patients.
abstract: Calcium channel blockers (CCB) are widely used in cardiovascular medicine expressing high hopes upon decreasing cardiovascular risk, morbidity and mortality. Here, the potency of CCBs on 58 Romanian asymptomatic hypertensive patients, with no atherothrombotic cardiovascular disease, was studied by clinical and in silico methods. In our study, arterial elasticity/stiffness was assessed; anthropometric, metabolic (lipidic) parameters were quantified. We concluded that lercanidipine 10 mg once daily, during three weeks, is able to dramatically improve central aortic systolic blood pressure, aortic pulse wave velocity. Lipid profile improvement is an essential condition to improve elastic vascular properties in order to decrease the risk for further cardiovascular events. Besides, the potency of lercanidipine is expressed as the contribution of molecular descriptors (van der Waals and solvent accessible surface areas), electronic (molecular polarisability) and hydrophobic (water/octanol partition coefficient) by means of blocker effect on calcium channel, compared with cilnidipine and other 30 dihydropyridines, using molecular simulation techniques.
authors.forename: Daniel
authors.initials: D
authors.lastname: Duda-Seiman
authors.forename: Corina
authors.initials: C
authors.lastname: Duda-Seiman
authors.affiliation: Department of Analytical Chemistry, Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy Timisoara, 2nd E.Murgu Sq., Timisoara-300041, Romania. fborcan@umft.ro.
authors.forename: Florin
authors.initials: F
authors.lastname: Borcan
authors.forename: Livia-Cristina
authors.initials: LC
authors.lastname: Borcan
authors.forename: Silvia
authors.initials: S
authors.lastname: Mancas
authors.forename: Speranta
authors.initials: S
authors.lastname: Avram
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000737:chemistry / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000737:chemistry / Q000627:therapeutic use*; D004095:Dihydropyridines / Q000737:chemistry / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D063177:Pulse Wave Analysis; D059289:Vascular Stiffness / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; C065927:cilnidipine; C060343:lercanidipine